The head of US pharmaceutical conglomerate Pfizer defended plans to acquire UK rival AstraZeneca as Pfizer chief executive Ian Read spoke to a panel of British lawmakers about the deal.
”We don’t see any substantial antitrust issues on this deal anywhere in the world,” Read said.
The merger would mark the largest acquisition of a UK company by a foreign firm and create a pharmaceutical behemoth. No merger deal has been officially made, but Pfizer has offered $106 billion to acquire the UK firm – a figure AstraZeneca said was too low.
Experts are eyeing the proposed acquisition carefully and say if a deal is ever reached it would likely face intense scrutiny from competition regulators. Earlier reports said UK authorities would likely face a battle with the European Commission to review such a deal.
Full content: Business Report
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Power Industry Shake-Up: Constellation Energy to Buy Calpine in Massive $26.6B Deal
Jan 10, 2025 by
CPI
DOJ Sues to Block $570 Million Deal Between AMEX GBT and CWT
Jan 10, 2025 by
CPI
Meta Accused of Using Pirated Books to Train AI, Court Documents Reveal
Jan 9, 2025 by
CPI
Frank McCourt’s Project Liberty Eyes TikTok US Acquisition as Deadline Looms
Jan 9, 2025 by
CPI
Disney-Fubo Deal Sparks Antitrust Concerns from DirecTV, Dish, and EchoStar
Jan 9, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand